Get complete Patent Opposition Report for Incyte

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Your Report Now

Latest oppositions filed by Incyte

Explore patent oppositions filed by Incyte against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Patent NumberTitleApplicantOpposition Date
EP3450434Deuterated Derivatives Of RuxolitinibCONCERT PHARMACEUTICALSNov 23, 2021

Explore Incyte's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Patent NumberGrant DateTitleTotal Oppositions
EP2919766May 26, 2021Sustained-Release Dosage Forms Of Ruxolitinib8
EP3070090Dec 12, 2018Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile1
EP3184526Oct 3, 2018Pyrrolo[2,3-D]Pyrimidine Derivatives As Janus Kinase Inhibitor1
EP2671882Feb 21, 2018Pyrrolo[2,3-B]Pyridin-4-Yl-Amines And Pyrrolo[2M3-B]Pyrimidin-4-Yl-Amines As Janus Kinase Inhibitors2
EP3050882Jan 31, 2018Piperidin-4-Yl Azetidine Derivatives As Jak1 Inhibitors1
EP2300455Jul 19, 2017Salts Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Yl-Methyl) - Imidazo [1, 2-B] [1, 2, 4] Triazin-2-Yl] Benzamide And Processes Related To Preparing The Same2